Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Selvaggi

Showing results (81-90 of 392) with videos related to

Pageof 40
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 27, 2001
Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancerS Novello, L Galli, A Antonuzzo, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 1, 1995
The influence of donor specific vertebral body derived bone marrow cell infusion on canine islet allograft survival without irradiation conditioning of the recipientM D Brendel, S S Kong, R D Schachner, et al.
Transplantation Proceedings|August 16, 2006
Growth after intestinal transplant in childrenT Ueno, T Kato, K Revas, et al.
Transplantation Proceedings|August 16, 2006
Analysis of rejection episodes in over 100 pediatric intestinal transplant recipientsG Selvaggi, T Kato, J J Gaynor, et al.
Transplantation Proceedings|February 23, 2010
International grading scheme for acute cellular rejection in small-bowel transplantation: single-center experienceP Ruiz, H Takahashi, V Delacruz, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2006
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapyF Cappuzzo, S Novello, F De Marinis, et al.
Seminars in Oncology|September 5, 1998
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trialL Crinò, A M Mosconi, G V Scagliotti, et al.
Transplantation Proceedings|August 16, 2006
CD55 and CD59 deficiency in transplant patient populations: possible association with paroxysmal nocturnal hemoglobinuria-like symptoms in Campath-treated patientsP Ruiz, D Weppler, P Tryphonopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2006
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabineP Ceppi, M Volante, S Novello, et al.
Clinical Transplants|July 22, 2008
Liver transplantation at the Miami Transplant Institute: a 14-year single-center experienceJ Moon, E Island, D Weppler, et al.
Pageof 40

Showing results (81-90 of 392) with videos related to

Sort By:
Pageof 40
Lung Cancer (Amsterdam, Netherlands)|October 27, 2001
Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancerS Novello, L Galli, A Antonuzzo, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 1, 1995
The influence of donor specific vertebral body derived bone marrow cell infusion on canine islet allograft survival without irradiation conditioning of the recipientM D Brendel, S S Kong, R D Schachner, et al.
Transplantation Proceedings|August 16, 2006
Growth after intestinal transplant in childrenT Ueno, T Kato, K Revas, et al.
Transplantation Proceedings|August 16, 2006
Analysis of rejection episodes in over 100 pediatric intestinal transplant recipientsG Selvaggi, T Kato, J J Gaynor, et al.
Transplantation Proceedings|February 23, 2010
International grading scheme for acute cellular rejection in small-bowel transplantation: single-center experienceP Ruiz, H Takahashi, V Delacruz, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2006
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapyF Cappuzzo, S Novello, F De Marinis, et al.
Seminars in Oncology|September 5, 1998
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trialL Crinò, A M Mosconi, G V Scagliotti, et al.
Transplantation Proceedings|August 16, 2006
CD55 and CD59 deficiency in transplant patient populations: possible association with paroxysmal nocturnal hemoglobinuria-like symptoms in Campath-treated patientsP Ruiz, D Weppler, P Tryphonopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2006
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabineP Ceppi, M Volante, S Novello, et al.
Clinical Transplants|July 22, 2008
Liver transplantation at the Miami Transplant Institute: a 14-year single-center experienceJ Moon, E Island, D Weppler, et al.
Pageof 40